close

  
Filter options:

Freebase Commons Common /common

  • Omeprazole (Lake Erie Medical ), manufactured drug form of Omeprazole, 40mg/capsule omeprazole delayed release capsule, NDC 35356-644

Freebase Commons Business /business

Freebase Commons Medicine /medicine

Section name Section URI Prominent warning Highlight text Subject manufactured drug Section LOINC code
  • false
  • Known hypersensitivity to any component of the formulation or substituted benzimidazoles (angioedema and anaphylaxis have occurred) (4)
  • -
  • 34070-3
  • false
  • Symptomatic response does not preclude the presence of gastric malignancy ( 5.1). Atrophic Gastritis: has been noted with long-term therapy (5.2). Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increaded risk for osteoporosis-related fractures of the nip, wrist, or spine (5.3). Diminished anti-platelet activity of clopidogrel due to impaired CYP2C19 function by 80 mg omeprazole (5.4). Triple therapy for H. pylori – there are risks due to antibiotics; see separate prescribing information for individual antibiotics (5.5, 5.6). Hypomagnesemia has been reported rarely with prolonged treatment with PPIs (5.7). Avoid concomitant use of Omeprazole Delayed-Release Capsules with St. John's Wort or rifampin due to the potential reduction in omeprazole concentrations (5.8, 7.3). Interactions with diagnostic investigations for Neuroendocrine Tumors: Increases in intragastric pH may result in hypergastrinemia and enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with diagnostic investigations for neuroendocrine tumors (5.9, 12.2).
  • -
  • 43685-7
  • false
  • -
  • -
  • 34076-0
  • false
  • -
  • -
  • 34089-3
  • false
  • -
  • -
  • 34088-5
  • false
  • Atazanavir and nelfinavir: Omeprazole Delayed-Release Capsules reduce plasma levels of atazanavir and nelfinavir. Concomitant use is not recommended (7.1). Saquinavir: Omeprazole Delayed-Release Capsules increase plasma levels of saquinavir. Monitor for toxicity and consider dose reduction of saquinavir (7.1). May interfere with drugs for which gastric pH affects bioavailability (e.g., ketoconazole, iron salts, ampicillin esters, and digoxin). Patients treated with Omeprazole Delayed-Release Capsules and digoxin may need to be monitored for increases in digoxin toxicity (7.2). Co-administration of clopidogrel with 80 mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if given 12 hours apart (7). Cilostazol: Omeprazole Delayed-Release Capsules increase systemic exposure of cilostazol and one of its active metabolites. Consider dose reduction of cilostazol (7.3). Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole Delayed-Release Capsules can prolong their elimination. Monitor and determine need for dose adjustments (7.3). Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time (7.3). Combined inhibitor of CYP 2C19 and 3A4 (e.g., voriconazole) may raise omeprazole levels (7.3). Tacrolimus: Omeprazole Delayed-Release Capsules may increase serum levels of tacrolimus (7.4).
  • -
  • 34073-7
  • false
  • -
  • -
  • 34069-5
  • false
  • -
  • -
  • 42230-3
  • false
  • -
  • -
  • 34068-7
  • false
  • -
  • -
  • 34092-7

Comments

Hide